What is the recommended diagnostic work‑up and treatment for transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnostic Work-Up and Treatment for ATTR Cardiomyopathy

For suspected ATTR-CM, obtain echocardiography showing increased LV wall thickness, screen for plasma cell disorder with serum/urine immunofixation and free light chains, and if negative, proceed directly to 99mTc-PYP bone scintigraphy—grade ≥2 myocardial uptake without a monoclonal protein is diagnostic and eliminates the need for endomyocardial biopsy; once diagnosed, initiate tafamidis immediately as it improves survival and functional capacity. 1

Diagnostic Algorithm

Step 1: Clinical Suspicion - Red Flags

Look for these specific clinical features that should trigger ATTR-CM evaluation 1, 2:

  • Cardiac: Unexplained LV wall thickening (≥12mm), heart failure with preserved ejection fraction (HFpEF) of unclear cause, low-voltage ECG despite increased wall thickness, atrial fibrillation with heart failure
  • Extracardiac: Bilateral carpal tunnel syndrome (especially preceding heart failure by years), lumbar spinal stenosis, autonomic neuropathy (orthostatic hypotension, erectile dysfunction), unexplained peripheral neuropathy
  • Demographics: Age >60 years, male predominance (particularly for wild-type ATTR)

Step 2: Initial Diagnostic Testing

When ATTR-CM is suspected 1:

  1. Echocardiography: Look for increased LV wall thickness, granular sparkling appearance, biatrial enlargement, reduced global longitudinal strain with apical sparing
  2. Cardiac MRI (if available): Diffuse late gadolinium enhancement, elevated extracellular volume fraction
  3. ECG: Low voltage relative to wall thickness, pseudoinfarct pattern
  4. Biomarkers: Elevated NT-proBNP and troponin (for staging, not diagnosis)

Step 3: Exclude Light Chain Amyloidosis

This step is mandatory before proceeding 1:

  • Serum and urine immunofixation electrophoresis
  • Serum free light chain assay
  • If any monoclonal protein is detected, hematology referral is required to rule out AL amyloidosis

Step 4: Bone Scintigraphy (Non-Invasive Diagnosis)

If no monoclonal protein is found 1:

  • Perform 99mTc-PYP (or DPD/HMDP outside US) cardiac scintigraphy
  • Grade ≥2 myocardial uptake + absence of monoclonal protein + appropriate cardiac imaging = diagnostic for ATTR-CM
  • Endomyocardial biopsy is NOT needed when these criteria are met

Step 5: TTR Gene Sequencing

Perform in ALL diagnosed ATTR-CM patients 1:

  • Differentiates wild-type (ATTRwt) from hereditary (ATTRm)
  • Required even without family history due to variable penetrance
  • If variant detected, genetic counseling for family members is indicated

Step 6: Biopsy (Only If Needed)

Endomyocardial or extracardiac biopsy with Congo red staining is reserved for 1:

  • Equivocal scintigraphy results
  • Presence of monoclonal protein requiring differentiation from AL amyloidosis
  • Tissue must undergo immunofluorescence or mass spectrometry to confirm ATTR subtype

Treatment Recommendations

Disease-Modifying Therapy

Tafamidis is the primary disease-modifying treatment with Class 1 recommendation 3:

  • TTR stabilizer that prevents tetramer dissociation
  • Proven mortality benefit and improved functional capacity
  • Initiate early in disease course for maximum benefit 4, 5
  • More effective when started before advanced cardiac dysfunction develops

Additional Treatment Options Under Development 5, 6, 7:

  • TTR gene silencers: Patisiran, vutrisiran, eplontersen (suppress hepatic TTR synthesis)
  • Acoramidis: Alternative TTR stabilizer
  • Gene editing: Nexiguran ziclumeran (CRISPR-Cas9 technology, single-dose potential)
  • Monoclonal antibodies: Cormitug, ALXN220, AT-02 (target amyloid removal—major unmet need)

Supportive Heart Failure Management

Standard heart failure therapies with important caveats:

  • Diuretics: For volume management (often require higher doses)
  • Avoid or use cautiously: Digoxin (binds to amyloid fibrils), calcium channel blockers, beta-blockers (may worsen conduction abnormalities)
  • Arrhythmia management: High prevalence of atrial fibrillation; consider anticoagulation regardless of CHA₂DS₂-VASc score
  • Pacemaker/ICD: For conduction disease or ventricular arrhythmias as indicated

Monitoring Treatment Response 3

Assess efficacy using combination of:

  • Biomarkers: NT-proBNP, cardiac troponins, eGFR
  • Imaging: Echocardiographic global longitudinal strain, CMR extracellular volume fraction
  • Clinical metrics: Functional status (6-minute walk test), hospitalizations, survival

Prognostic Stratification

Staging system for ATTR-CM 1:

  • Stage 1: NT-proBNP <3000 pg/mL AND eGFR ≥45 mL/min
  • Stage 2: One threshold met
  • Stage 3: NT-proBNP ≥3000 pg/mL AND eGFR <45 mL/min

Higher stages correlate with worse prognosis; untreated median survival is 2-6 years from diagnosis.

Critical Pitfalls to Avoid

  1. Misdiagnosis as hypertrophic cardiomyopathy or HFpEF: Always consider ATTR-CM in older patients with unexplained LV hypertrophy 1
  2. Delaying diagnosis: Treatment is more effective early; don't wait for advanced symptoms 4, 8
  3. Skipping monoclonal protein screening: Cannot diagnose ATTR-CM without excluding AL amyloidosis 1
  4. Performing unnecessary biopsies: Grade ≥2 PYP uptake without monoclonal protein is diagnostic 1
  5. Not genotyping diagnosed patients: Essential for family counseling and understanding prognosis 1
  6. Withholding treatment due to cost concerns: Individual patient benefit in survival and symptoms justifies therapy 3

Multidisciplinary Care Model

ATTR-CM management requires collaboration 3:

  • Primary care providers for initial recognition
  • Community cardiologists for initial workup
  • Amyloid specialists at referral centers for complex cases
  • Telehealth expanding access to specialists, particularly for rural/underserved populations

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.